The Mechanism of Propofol in Treating Depression-like Behaviors Based on Network Pharmacology and Experimental Validation

Authors

  • Jiarong Wang
  • Jinchen Xiang
  • Xuemei Han
  • Xueliang Shang

DOI:

https://doi.org/10.54097/17trx627

Keywords:

Network Pharmacology, Propofol, Depression, GRM5, mGluR5

Abstract

Objective: To explore the potential mechanism of propofol in improving antidepressant-like behavior through network pharmacology and animal experimental validation, providing theoretical and experimental support for the development of novel antidepressant drugs based on propofol. Methods: 1. The targets of propofol and the disease targets of depression were screened through Swiss Target prediction, Super-pred, SEA, Drugbank, CTD, GeneCards, OMIM, and TTD databases. A protein-protein interaction (PPI) network was constructed, and the core targets were screened and visualized using CytoScape 3.10.2 software. Additionally, GO and KEGG enrichment analyses of the intersection targets were performed using the Metascape database. 2. Thirty male C57BL/6 mice were randomly divided into the CON group, LH model group, and PRO treatment group, with 10 mice in each group. The sucrose preference test, forced swim test, and tail suspension test were conducted to determine whether the depression model was successfully established and to assess the improvement effect of propofol on antidepressant-like behavior. 3. The pathological morphological changes of hippocampal neurons in the three groups of mice were observed through HE staining experiments. The expression of mGluR5 protein in the hippocampus was analyzed by Western blot. Results: 1. Network pharmacology analysis indicated that propofol may exert antidepressant effects by acting on core genes such as ALB, ESR1, NFKB1, HSP90AB1, and EGFR. These core target genes were mainly enriched in biological processes such as synaptic transmission and membrane potential regulation; they involved cellular components such as GABA receptor complexes and synaptic membranes; and they included molecular functions such as neurotransmitter receptor activity. Additionally, propofol may exert antidepressant effects through signaling pathways such as neuroactive ligand-receptor interaction, morphine addiction, and GABAergic synapse. 2. Compared with the CON group, the sucrose preference rate of mice in the LH model group significantly decreased, while the immobility time in the forced swim test and tail suspension test significantly increased. Compared with the LH model group, the sucrose preference rate of mice in the PRO treatment group significantly increased, and the immobility time significantly decreased. 3. The HE results showed that compared with the CON group, the number of neurons in the LH group decreased, with loose arrangement, pycnotic and deeply stained nuclei with blurred boundaries. However, the number of necrotic neurons in the PRO group significantly decreased. The Western blot results showed that compared with the CON group, the expression level of mGluR5 protein in the LH model group significantly increased, while it significantly decreased in the PRO treatment group compared with the LH model group. Conclusion: Propofol may exert antidepressant effects by regulating the expression of mGluR5, improving antidepressant-like behavior, and reducing hippocampal neuronal necrosis.

Downloads

Download data is not yet available.

References

[1] Ding Yanqiu, Yuan Huimin, Chen Xiao, et al. Progress of modern medical research and treatment of depression [J]. Western Medicine, 2019,36(04):614-618. (in Chinese)

[2] COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700-1712.

[3] Su H. The pathogenesis of depression and the research status and progress of commonly used antidepressant drugs [J]. Journal of Modern Medicine and Health Research, 2019,7 (21): 16-19.

[4] Marwaha S, Palmer E, Suppes T, et al. Novel and emerging treatments for major depression. Lancet. 2022 Dec 16: S0140-6736(22)02080-3.

[5] MICKEY B J, WHITE A T, ARP A M, et al. Propofol for Treatment-Resistant Depression: A Pilot Study [J]. International Journal of Neuropsychopharmacology, 2018, 21(12): 1079-89.

[6] Zhu XN, Li J, Qiu GL, et al. Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter. Neuron. 2023;111(10):1626-1636.e6.

[7] Zhang P, Zhang D, Zhou W, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief Bioinform. 2023;25(1): bbad518.

[8] Cui L, Li S, Wang S, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024 Feb 9;9(1):30.

[9] Platholi J, Hemmings HC. Effects of General Anesthetics on Synaptic Transmission and Plasticity. Curr Neuropharmacol. 2022;20(1):27-54.

[10] Liu Qiang, Hong Jiang, Li Xiaoyu. Mechanism of action and new clinical application of propofol [J]. Chinese Journal of Clinical Pharmacology and Therapeutics,2010,15(07):836-840. (in Chinese)

[11] Zhang Ying, Li Yuwen, Zhang Tiejun. Nonanesthetic effects and mechanism of propofol [J]. Chinese Pharmaceutical Industry, 2020, 29(19):4. (in Chinese)

[12] Wang YL, Wang L, Xu W, et al. Paraventricular thalamus controls consciousness transitions during propofol anaesthesia in mice. Br J Anaesth. 2023;130(6):698-708.

[13] Zhu Enni, Wu Chaoran, Liao Hong. Research progress of metabolic glutamate receptor 5 in central nervous system diseases [J]. Journal of China Pharmaceutical University, 2019,52(6):751-758. (in Chinese)

[14] Wei Le, Huang Xinyi, Tang Zhongqiu, et al. Research progress of hippocampal synaptic plasticity in prevention and treatment of depression [J]. Journal of Hubei University for Nationalities (Medical Edition),2021,38(03):73-76. (in Chinese)

[15] MCGRATH T, BASKERVILLE R, ROGERO M, et al. Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases [J]. Nutrients, 2022, 14(5).

[16] Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul;16(7):472-486.

[17] ZHU Enni,WU Chaoran,LIAO Hong. Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases [J]. J China Pharm Univ,2021, 52(6):751–758.

[18] Kim Y, Kim J, Kang S, Chang KA. Depressive-like Behaviors Induced by mGluR5 Reduction in 6xTg in Mouse Model of Alzheimer's Disease. Int J Mol Sci. 2023;24(16):13010.

[19] ELMESEINY O S A, MüLLER H K. A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine [J]. Pharmacol Res, 2024, 200: 107081.

[20] Eng AG, Kelver DA, Hedrick TP, et al. Transduction of group I mGluR-mediated synaptic plasticity by beta-arrestin2 signalling [J]. Nat Commun,2016,7:13571.

[21] Murrough JW,Abdallah CG,Mathew SJ. Targeting glutamate signalling in depression: progress and prospects[J]. Nat Rev Drug Discov,2017,16(7):472-486.

Downloads

Published

22-11-2024

Issue

Section

Articles

How to Cite

Wang, J., Xiang, J., Han, X., & Shang, X. (2024). The Mechanism of Propofol in Treating Depression-like Behaviors Based on Network Pharmacology and Experimental Validation. International Journal of Biology and Life Sciences, 8(1), 54-59. https://doi.org/10.54097/17trx627